DCM
ZVRA icon

Driehaus Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Driehaus Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-9,049
Closed -$650K – 664
2016
Q3 		$650K Sell
9,049
-109
-1% -$7.75K 0.02% 404
2016
Q2 		$583K Sell
9,158
-6,143
-40% -$1.01M 0.02% 410
2016
Q1 		$3.55M Sell
15,301
-430
-3% -$104K 0.12% 184
2015
Q4 		$5M Buy
15,731
+2,078
+15% +$564K 0.17% 138
2015
Q3 		$4.23M Buy
13,653
+5,198
+61% +$1.59M 0.15% 157
2015
Q2 		$2.48M Buy
+8,455
New +$1.84M 0.09% 302

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Driehaus Capital Management's ZVRA Position: Q4 2016 in Review

Driehaus Capital Management sold out of Zevra Therapeutics (ZVRA) in Q4 2016, closing a stake of 9,049 shares — an estimated $650K sold.

Driehaus Capital Management first reported a position in ZVRA in Q2 2015 and held it in 6 quarters. The position peaked at $5M in Q4 2015. 36 funds tracked by Wall St. Rank hold ZVRA as of Q4 2016.

  • Driehaus Capital Management reported no remaining Zevra Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Driehaus Capital Management sold 9,049 Zevra Therapeutics shares in Q4 2016, an estimated $650K.
  • Driehaus Capital Management first reported a position in Zevra Therapeutics in Q2 2015 and held it in 6 quarters.
  • Driehaus Capital Management's Zevra Therapeutics position peaked at $5M in Q4 2015.
  • 36 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2016.

Based on Driehaus Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.